Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesInhalerx Ltd

Inhalerx Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
None AUD 0.00(0%)
Last update at 2026-05-20T06:45:05.072009Z
Market Cap
6.90M

Momentum Score

…

Nexalis Therapeutics Limited, a biotechnology company, develops and sells registrable inhaled drug-device combinations in Australia. It is developing IRX-211 that has completed Phase 1 clinical trial for the treatment of Breakthrough Cancer Pain (BTcP); and IRX-616a that is in preclinical trial for panic disorder (PD). The company was formerly known as InhaleRx Limited and changed its name Nexalis Therapeutics Limited in January 2026. Nexalis Therapeutics Limited was incorporated in 2016 and is headquartered in Melbourne, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
0.02
Low
0.05
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
0.83M
Revenue Per Share
0.00
Gross Profit TTM
0.83M
Debt / Equity
-0.26
ROE
-402.12%
Net Debt
0.30M
ROCE
288.23%
Diluted EPS TTM
-0.01

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -1.62M -1.28M -2.65M -1.90M -1.11M
Net income -1.62M -1.28M -1.44M -1.90M -1.11M
Selling general administrative 0.30M 0.83M 0.83M 0.51M 0.56M
Selling and marketing expenses - 0.06M 0.03M 0.03M 0.05M
Gross profit - 0.34M 1.20M 0.02M 0.05M
Reconciled depreciation - - - 0.00M 0.00M
Ebit - - -1.42M -1.92M -1.13M
Ebitda - - -1.41M -1.92M -1.12M
Depreciation and amortization - 1.35M 0.01M 0.00M 0.00M
Operating income -2.47M -1.33M -1.39M -1.92M -1.13M
Other operating expenses - 1.66M 2.59M 1.95M 1.29M
Interest expense 0.14M 0.09M 0.01M - 0.00M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Interest income 0.01M 0.00M 0.00M 0.02M 0.00M
Net interest income -0.13M -0.08M -0.01M 0.02M 0.00M
Income tax expense - -0.40M -1.20M -0.02M -0.00M
Total revenue - 0.34M 1.20M 0.02M 0.17M
Total operating expenses - 1.66M 2.59M 1.95M 1.18M
Cost of revenue - - - 0.00M 0.12M
Total other income expense net 0.99M 0.05M -1.26M 0.01M 0.01M
Net income from continuing ops -1.62M -1.21M -1.44M -1.90M -1.11M
Net income applicable to common shares - -1.21M -1.44M -1.93M -1.11M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 1.21M 0.65M 1.58M 2.26M 2.93M
Intangible assets - - - 0.01M 0.01M
Other current assets - 0.45M 0.06M -0.00M 0.00M
Total liab 2.38M 0.78M 0.91M 0.36M 0.25M
Total stockholder equity -1.18M -0.13M 1.00M 1.90M 2.68M
Other current liab - 0.17M 0.17M 0.26M 0.18M
Common stock - 14.53M 14.08M 13.93M 12.90M
Capital stock 15.15M - - 13.93M 12.90M
Retained earnings -16.00M -14.45M -13.17M -11.70M -9.25M
Cash 0.44M 0.19M 0.72M 2.13M 2.80M
Cash and equivalents - - - 2.13M 2.80M
Total current liabilities 2.07M 0.78M 0.91M 0.36M 0.25M
Net debt 0.30M -0.16M -0.16M -2.13M -2.80M
Short term debt - 0.03M 0.56M 0.00M 0.00M
Short long term debt 0.43M - - - -
Short long term debt total - 0.03M 0.56M - -
Other stockholder equity - 0.00M - -0.03M -0.97M
Property plant equipment - - - 0.00M 0.01M
Total current assets 1.21M 0.65M 1.58M 2.24M 2.91M
Net tangible assets - - - 1.91M 2.66M
Net receivables - - 0.80M 0.03M 0.02M
Long term debt 0.32M - - - -
Inventory - - - 0.08M 0.02M
Accounts payable 1.46M 0.57M 0.18M 0.10M 0.07M
Accumulated other comprehensive income - -0.21M 0.09M -0.30M -0.97M
Non current assets total 0.00M - - 0.01M 0.02M
Long term debt total - - - 0.00M 0.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - 0.00M - -0.00M -0.03M
Change to liabilities - - - 0.08M -0.12M
Total cashflows from investing activities - 0.00M 0.00M -0.00M -0.03M
Net borrowings 0.65M -0.15M 0.55M - -
Total cash from financing activities 1.13M -0.15M 0.54M 1.18M 2.26M
Change to operating activities - - - -0.01M 0.04M
Net income -1.62M -1.28M -1.44M -1.90M -1.11M
Change in cash 0.24M -0.52M -1.42M -0.67M 1.08M
Begin period cash flow 0.19M 0.72M 2.13M 2.80M 1.72M
End period cash flow 0.44M 0.19M 0.72M 2.13M 2.80M
Total cash from operating activities - -0.37M -1.96M -1.85M -1.15M
Issuance of capital stock 0.54M - - 1.20M 2.27M
Depreciation - - - 0.00M 0.00M
Other cashflows from investing activities - 0.00M - - -
Change to inventory - - - - -0.02M
Change to account receivables - 0.36M -0.77M - 0.06M
Sale purchase of stock -0.06M -0.01M -0.00M -0.02M -0.01M
Other cashflows from financing activities - -0.55M -0.00M -0.00M -0.03M
Change to netincome - - - 0.05M 0.00M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.03M
Change in working capital - 0.76M -0.59M 0.02M 0.00M
Stock based compensation - 0.02M 0.06M - -
Other non cash items - 0.15M 0.07M - -
Free cash flow -0.89M -0.37M -1.96M -0.00M -0.03M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
CSL
CSL Ltd		 2.86
1.42%		 204.54 - 22.57 6.15 4.48 4.82 10.06
TLX
TELIX Pharmaceuticals Ltd		 -0.32
2.28%		 13.70 93.87 166.67 5.37 6.37 3.85 47.29
NEU
Neuren Pharmaceuticals Ltd		 -0.30
1.25%		 23.66 154.93 36.36 42.38 7.52 31.95 160.40
MSB
Mesoblast Ltd		 -0.07
3.69%		 1.96 - 454.55 23.43 3.36 18.28 -9.86

Profile*

Inhalerx Ltd

Nexalis Therapeutics Limited, a biotechnology company, develops and sells registrable inhaled drug-device combinations in Australia. It is developing IRX-211 that has completed Phase 1 clinical trial for the treatment of Breakthrough Cancer Pain (BTcP); and IRX-616a that is in preclinical trial for panic disorder (PD). The company was formerly known as InhaleRx Limited and changed its name Nexalis Therapeutics Limited in January 2026. Nexalis Therapeutics Limited was incorporated in 2016 and is headquartered in Melbourne, Australia.

505 Little Collins Street, Melbourne, VIC, Australia, 3000

61 3 8678 4091

https://inhalerx.com.au

Name Title Year Born
Mr. Darryl Davies Chief Exec. Officer NA
Dr. Robert Jenny Ph.D. Chief Scientific Officer NA
Mr. Srinivasa Rao Suryadevara Exec. VP 1968
Ms. Nova Anne Taylor Company Sec. NA
Ms. Elizabeth Spooner Joint Company Sec. NA
Mr. Darryl Davies B.Sc. Chief Executive Officer NA
Dr. Robert Jenny B.A., B.Sc., Ph.D. Chief Scientific Officer NA
Mr. Srinivasa Rao Suryadevara Executive Vice President 1968
Mr. James Stephen Barrie CPA Company Secretary NA
Mr. Darryl Davies B.Sc. Chief Executive Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…